Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.
By H. Collard, T. King, B. B. Bartelson, J. Vourlekis, M. Schwarz, K. Brown. American Journal of Respiratory and Critical Care Medicine, 2003
744 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/dd859b6a5a6b7d3fe056689b3caacc3877933110
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. (2005, neutral): “Despite the fact that this secondary endpoint was the main reason for the DSMB’s recommendation to abort the study, we express caution in drawing conclusions based solely on this result for the following reasons: (1) limited follow-up data in the study, (2) a consensus among experts worldwide regard”
- A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. (2015, positive): “…in detail more recently, 26 and consistent clinical predictors of worse survival include older age, dyspnea, low or declining pulmonary function, 28 – 30 pulmonary hypertension, concomitant emphysema, extensive radiographic involvement, low exercise capacity or exertional desaturation, 27,31…”
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline (2022, background): “Despite these limitations, change in DLCO (corrected for Hb) is a consistent and strong predictor of mortality in patients with a variety of fibrotic lung diseases (130, 131).”
- Clinical course and prediction of survival in idiopathic pulmonary fibrosis. (2011, background): “In general, factors that are associated with shortened survival time include: older age, smoking history, lower body mass index (BMI), more severe physiologic impairment, greater radiologic extent of disease, and the development of other complications or conditions, in particular, pulmonary hyperten”
- High-dose acetylcysteine in idiopathic pulmonary fibrosis. (2005, neutral): “Respiratory tract infection† 22 20 (25) 27 24 (32)”
- Interstitial lung disease guideline (2008, background): “37–40 Collard et al, in a study of 81 patients with UIP, evaluated change in lung function over both 6 and 12 months.(37) Six-month changes in total lung capacity (TLC), FVC and TLCO predicted survival, with serial FVC the strongest prognostic determinant.”